HALOPERIDOL DECANOATE

Post-LOE

haloperidol decanoate

Pfizer

ANDAINJECTIONINJECTABLE

Approved

May 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

HALOPERIDOL DECANOATE (haloperidol decanoate) by Pfizer is 12. Approved for schizophrenia in adults, schizophrenia. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of haloperidol decanoate for the treatment of schizophrenia in adults is unclear. However, its effect in schizophrenia could be mediated through its activity as an antagonist at central dopamine type 2 receptors. Haloperidol also binds to alpha-1…

Worked on HALOPERIDOL DECANOATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

HALOPERIDOL DECANOATE

Mechanism of Action

Indications (2)